There were some positive points in the data that Amgen presented Friday, Goldman Sachs analyst Terrence Flynn said. Then, Amgen said Repatha cut down on major adverse cardiovascular events by 15%. But analysts broadly expected 20% or better, he said.
Terence Flynn (1979-1983), Dave Whitton (2002-2003), Mostafa Hindi (2003-2007), Robert Williams (1984-1988), Steven Main (1975-1979), Ladis Kvita (1980-1984)